Waters - WAT Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" WAT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WAT, but not buy additional shares or sell existing shares.
View WAT analyst ratings or view top-rated stocks.

7 brokers have issued 1-year price targets for Waters' shares. Their WAT share price forecasts range from $317.00 to $380.00. On average, they anticipate the company's share price to reach $349.67 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts price targets for WAT or view top-rated stocks among Wall Street analysts.

Waters' stock was trading at $342.58 at the beginning of the year. Since then, WAT stock has decreased by 1.6% and is now trading at $337.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our WAT earnings forecast.

Waters will be holding an earnings conference call on Wednesday, February 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Waters Co. (NYSE:WAT) announced its quarterly earnings data on Tuesday, November, 2nd. The medical instruments supplier reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.34 by $0.32. The medical instruments supplier earned $659.23 million during the quarter, compared to analysts' expectations of $652.28 million. Waters had a net margin of 23.63% and a trailing twelve-month return on equity of 189.79%. During the same quarter in the prior year, the company earned $2.16 earnings per share.
Read the conference call transcript.

13 employees have rated Waters Chief Executive Officer Udit Batra on Glassdoor.com. Udit Batra has an approval rating of 100% among the company's employees. This puts Udit Batra in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), Raytheon Technologies (RTX), CVS Health (CVS), Home Depot (HD), Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Verizon Communications (VZ), Cisco Systems (CSCO) and Walmart (WMT).

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters' stock is owned by many different retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (0.68%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Newport Trust Co (0.39%), Bank of Montreal Can (0.37%), DekaBank Deutsche Girozentrale (0.37%) and Allspring Global Investments Holdings LLC (0.29%). Insiders that own company stock include Christopher A Kuebler, Christopher J Oconnell, Edward Conard, Ian King, Joann A Reed, Keeley A Aleman, Linda Baddour, Michael C Harrington, Michael J Berendt, Robert G Carson, Sherry Buck and Thomas P Salice.
View institutional ownership trends.

Shares of WAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WAT stock can currently be purchased for approximately $337.04.

Waters (NYSE:WAT) has a market capitalization of $20.02 billion and generates $2.79 billion in revenue each year. The medical instruments supplier earns $692.84 million in net income (profit) each year or $11.46 on an earnings per share basis.

The company employs 7,800 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The official website for the company is www.waters.com. The medical instruments supplier can be reached via phone at (508) 478-2000, via email at investor_relations@waters.com, or via fax at 508-872-1990.